



PATENT  
ATTORNEY DOCKET NO.: 056291-5038

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of: )  
)  
CAMERON et al. )  
)  
Appln. No.: 09/889,409 ) Group Art Unit: 1614  
)  
Filed: February 22, 2002 ) Examiner: Weddington, Kevin  
)  
FOR: USE OF 3-HYDROXY-3- )  
METHYLGLUTARYL COENZYME A )  
REDUCTASE INHIBITORS FOR THE )  
MANUFACTURE OF A MEDICAMENT )  
FOR THE TREATMENT OF DIABETIC )  
NEUROPATHY )

Commissioner for Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **Mail Stop** \_\_\_\_\_  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Date: March 11, 2004

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Attached is a Form PTO-1449 listing the enclosed documents, which were recently cited in a corresponding Russian application.


This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Please charge the Rule 17(p) official fee required by Rule 97(c) to our Deposit Account No. 50-0310 under Order No. 056291-5038.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: March 11, 2004  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:mk

By:

---

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.	Client Ref.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		056291-5038	
		Applicant: CAMERON et al.	
		Appl. No.: 09/889,409	
		Filing Date: February 22, 2002	
Date: March 11, 2004	Page 1 of 1	Examiner: Weddington, K.	Group Art Unit: 1614

U.S. PATENT DOCUMENTS							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						
	DR						

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name	Enclosed	No	Enclosed	No
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
	GR	McClellan et al., "Candesartan Cilexetil A Review of its Use in Essential Hypertension", Drugs, 1998, pp. 847-869							
	HR	Graham-Smith et al., "Oxford Handbook on Clinical Pharmacology and Pharmacotherapy", Moscow, "Meditsina" 2000, part 10 (Partial Translation)							
	IR	Balabolkin, "Endocrinology", Moscow, "Universum Publishing" 1998, pp 427-430 and 420-421 (Partial Translation)							
	JR	Small Medical Encyclopedia, Moscow, "Meditsina", 199 pp. 110 (Partial Translation)							
	KR								
	LR								
	MR								
	NR								
	OR								
	PR								

Examiner	Date Considered:
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	